type here...
type here...
START FREE TRIAL

Healthcare

Technology & AIM&AHealthcareInformation TechnologyIndustrialsEnergy

Novartis Gene Therapy Approval: A New Multi-Billion Dollar Market?

Healthcare Ishan M. -
Novartis just scored a big win with a major Novartis gene therapy approval —and it could reshape the gene therapy landscape. On November 25,...

Johnson & Johnson Halda Acquisition: The $3.05 Billion Gamble!

Healthcare Ishan Majumdar -
Johnson & Johnson just made another big move. The company announced that it will buy Halda Therapeutics for $3.05 billion in cash, marking one...
spot_imgspot_img

Merck Cidara Acquisition: $9.2B Flu Drug Deal to Replace Keytruda

Healthcare Ishan Majumdar -
Merck isn’t waiting around for Keytruda’s patent clock to run out. On November 14, the pharma giant announced its...

Cogent Biosciences’ Cancer Drug Exploded to 136% —Can the Rally Actually Last?

Healthcare Ishan Majumdar -
It’s not every day you see a biotech stock jump 136% before lunch. But that’s exactly what happened with...

Premier Inc. Draws Buyout Interest From Patient Square Capital — Here’s Why This Deal Could Happen

Healthcare Ishan Majumdar -
Premier Inc, a healthcare group purchasing and technology company, has recently become the subject of acquisition interest from private...

GE Healthcare’s Neurology Bet: Can The Icometrix Acquisition Unlock The Alzheimer’s Diagnosis Market?

Healthcare Ishan Majumdar -
GE HealthCare has deepened its push into precision medicine with a strategic agreement to acquire icometrix, a Belgium-based firm...

Jamf Holding’s $1.4 Billion Shakeup: Citigroup Tapped As Vista Plots Its Exit

Healthcare Ishan Majumdar -
Jamf Holding Corp., a leading Apple-focused device management and security software provider, has become the subject of renewed M&A...

Kenvue Crashing?—New RFK Jr. Report May Blame Tylenol Use In Pregnancy For Autism

Healthcare Ishan Majumdar -
Shares of Kenvue Inc., maker of Tylenol, dropped roughly 10% in early September 2025 after media reports—primarily from The...
Load more

Novartis Gene Therapy Approval: A New Multi-Billion Dollar Market?

Healthcare Ishan M. -
Novartis just scored a big win with a major Novartis gene therapy approval —and it could reshape the gene...

Johnson & Johnson Halda Acquisition: The $3.05 Billion Gamble!

Healthcare Ishan Majumdar -
Johnson & Johnson just made another big move. The company announced that it will buy Halda Therapeutics for $3.05...

Merck Cidara Acquisition: $9.2B Flu Drug Deal to Replace Keytruda

Healthcare Ishan Majumdar -
Merck isn’t waiting around for Keytruda’s patent clock to run out. On November 14, the pharma giant announced its...

Cogent Biosciences’ Cancer Drug Exploded to 136% —Can the Rally Actually Last?

Healthcare Ishan Majumdar -
It’s not every day you see a biotech stock jump 136% before lunch. But that’s exactly what happened with...

Premier Inc. Draws Buyout Interest From Patient Square Capital — Here’s Why This Deal Could Happen

Healthcare Ishan Majumdar -
Premier Inc, a healthcare group purchasing and technology company, has recently become the subject of acquisition interest from private...

GE Healthcare’s Neurology Bet: Can The Icometrix Acquisition Unlock The Alzheimer’s Diagnosis Market?

Healthcare Ishan Majumdar -
GE HealthCare has deepened its push into precision medicine with a strategic agreement to acquire icometrix, a Belgium-based firm...

Jamf Holding’s $1.4 Billion Shakeup: Citigroup Tapped As Vista Plots Its Exit

Healthcare Ishan Majumdar -
Jamf Holding Corp., a leading Apple-focused device management and security software provider, has become the subject of renewed M&A...

Kenvue Crashing?—New RFK Jr. Report May Blame Tylenol Use In Pregnancy For Autism

Healthcare Ishan Majumdar -
Shares of Kenvue Inc., maker of Tylenol, dropped roughly 10% in early September 2025 after media reports—primarily from The...

Alcon’s Purchase Of STAAR Signals A New Chapter In Surgical Eye Care

Healthcare Ishan Majumdar -
Alcon’s recent agreement to acquire STAAR Surgical for $28 per share—representing a 59% premium to STAAR’s 90-day VWAP and...

Waters Corp Is Taking On Thermo Fisher & Danaher With This $17.5 Billion Becton Dickinson Acquisition!

Healthcare Ishan Majumdar -
Waters Corporation has officially entered a new phase of its growth journey with the $17.5 billion acquisition of Becton...

Bausch Health Strikes Bold With Durect Buy: A Strategic Bet On Liver Therapies?

Healthcare Ishan Majumdar -
Bausch Health Companies (NYSE:BHC) has made headlines with its definitive agreement to acquire liver-focused biotech Durect Corporation (NASDAQ:DRRX) for...

Axogen In Play? Here’s Why A Buyout Makes Sense At $18/Share

Healthcare Ishan Majumdar -
Axogen, Inc. (NASDAQ: AXGN) saw its stock jump nearly 4% after reports surfaced that the company is exploring a...
Load more

Baptista Research is a financial research house focused on the U.S. markets. We cover the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms.

Company

Headlines

Motorola Public Safety Technology: The Comeback Nobody Expected

0
When the iPhone crushed Motorola’s handset dominance, most thought...

Novartis Gene Therapy Approval: A New Multi-Billion Dollar Market?

0
Novartis just scored a big win with a major...

Google vs Nvidia AI Chips: Silicon War Begins

0
Alphabet's rise in artificial intelligence isn't just about fancy...

COP30 Impact on US Stocks: The 4 Quiet Tickers No One Is Watching (But Should Be)

0
The latest update from COP30 has added fresh momentum...

Newsletter

Get important news delivered directly to your inbox and stay connected!

Copyright © 2025 Baptista Research. All rights reserved.